Shanghai ZJ Bio-Tech Co., Ltd. researches, develops, produces, and sells molecular diagnostic reagents and instruments in China and internationally. Its offerings include nucleic acid and real-time PCR kits, along with consumables. The company serves the public health safety and clinical diagnostics sectors. Founded in 2005, it is based in Shanghai, China.
Why is Shanghai ZJ Bio-Tech Co. Ltd. A (688317.CG) moving?
Latest
▲2▼1
ZJ Bio-Tech: product approvals build pipeline, but losses widen
▲
New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.
These approvals are the main positive catalysts that could drive future sales and investor optimism.
Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.
The widening loss is the key fundamental negative that pressures the share price.
Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.
Buybacks are a capital action that can cushion the stock and show insider confidence.
ZJ Bio-Tech Repurchases 5.51 Million Shares for 105 Million Yuan
ZJ Bio-Tech announced on October 9 that as of September 30, 2026, the company had repurchased a cumulative 5.51 million shares, accounting for 2.90% of total share capital, with total repurchase funds of 105 million yuan and a repurchase price range of 14.71 yuan to 23.49 yuan per share. In the first half of 2026, ZJ Bio-Tech achieved revenue of 53.39 million yuan and a net loss attributable to the parent company of 40.59 million yuan.
Biotech & Genomic Medicine › Diagnostics & Precision Testing Capital
688317.CG · Capital · Positive ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan, a buyback that is a capital/valuation event for the company.
Zhejiang Bio's 2026 interim net loss widens to 40.5894 million yuan
Zhejiang Bio released its 2026 interim report. Total operating revenue was 53.3882 million yuan, down 10.55% year on year. Net profit attributable to the parent company was negative 40.5894 million yuan, a decrease of 30.7384 million yuan compared with the same period last year, with the loss widening. Net cash inflow from operating activities was 11.6042 million yuan, down 55.06% year on year. The company's asset-liability ratio was 10.82%, gross margin was 65.05%, return on equity was negative 1.24%, and diluted earnings per share was negative 0.23 yuan. The number of shareholders was 14,000, and the top ten shareholders held 42.87% of the total share capital.
ZJ Bio-Tech obtains Class III medical device registration certificate for monkeypox virus nucleic acid detection kit
ZJ Bio-Tech announced that its monkeypox virus nucleic acid detection kit, using fluorescent PCR method, has obtained a national Class III medical device registration certificate, valid from August 17, 2026 to August 16, 2031. The product is mainly used for in vitro qualitative detection of monkeypox virus nucleic acid in skin lesion samples from suspected monkeypox cases. In the first quarter of 2026, ZJ Bio-Tech achieved revenue of 25.42 million yuan and a net loss attributable to the parent company of 25.51 million yuan.
Zhejiang Bio has repurchased 4.37 million shares for a total of 85.92 million yuan
Zhejiang Bio announced that as of July 31, 2026, the company had repurchased a total of 4.37 million shares, representing 2.30% of its total share capital, for a total amount of 85.92 million yuan, at prices ranging from 14.71 yuan to 23.49 yuan per share. In the first quarter of 2026, the company achieved operating revenue of 25.42 million yuan, with a net loss attributable to shareholders of the parent company of 25.51 million yuan.
ZJ Bio-Tech HPV Nucleic Acid Test Product Receives National Class III Medical Device Registration Certificate
ZJ Bio-Tech announced that its product, the Human Papillomavirus 23-Type Nucleic Acid Genotyping Detection Kit (Fluorescent PCR Method), has recently obtained a National Class III Medical Device Registration Certificate, valid until July 28, 2031. The product is used for in vitro qualitative detection and genotype identification of 23 HPV types in female cervical exfoliated cell samples, covering mainstream high-risk and low-risk types. This certification will enrich the company's product portfolio, enhance its molecular diagnostics product matrix, and strengthen its market competitiveness in the HPV testing field.
ZJ Bio-Tech's Two Products Receive Certification from Vietnam's Ministry of Health
ZJ Bio-Tech announced that two of its products have recently received certification from Vietnam's Ministry of Health. After obtaining the certification, the relevant products can be sold in Vietnam and countries that recognize Vietnam's certification, which will help enhance the company's international competitiveness, expand its overseas product categories, and grow its international business. In the first quarter of 2026, ZJ Bio-Tech achieved revenue of 25.42 million yuan, with a net loss attributable to the parent company of 25.51 million yuan.
688317.CG · Regulation · Positive Two products received certification from Vietnam's Ministry of Health, enabling sales in Vietnam and other recognizing countries.
China